Effect of Metformin, Rapamycin, and Their Combination on Growth and Progression of Prostate Tumors in HiMyc Mice

Overview

Journal Cancer Prev Res (Phila)

Specialty Oncology

Date 2015 Apr 25

PMID 25908508

Citations 21

Authors

Achinto Saha

Jorge Blando

Lisa Tremmel

John DiGiovanni

Affiliations

Soon will be listed here.

Abstract

In this study, we compared the effect of oral administration of metformin (MET) and rapamycin (RAPA) alone or in combination on prostate cancer development and progression in HiMyc mice. MET (250 mg/kg body weight in the drinking water), RAPA (2.24 mg/kg body weight microencapsulated in the diet), and the combination inhibited progression of prostatic intraepithelial neoplasia lesions to adenocarcinomas in the ventral prostate (VP). RAPA and the combination were more effective than MET at the doses used. Inhibition of prostate cancer progression in HiMyc mice by RAPA was associated with a significant reduction in mTORC1 signaling that was further potentiated by the combination of MET and RAPA. In contrast, treatment with MET alone enhanced AMPK activation, but had little or no effect on mTORC1 signaling pathways in the VP of HiMyc mice. Further analyses revealed a significant effect of all treatments on prostate tissue inflammation as assessed by analysis of the expression of cytokines, the presence of inflammatory cells and NFκB signaling. MET at the dose used appeared to reduce prostate cancer progression primarily by reducing tissue inflammation whereas RAPA and the combination appeared to inhibit prostate cancer progression in this mouse model via the combined effects on both mTORC1 signaling as well as on tissue inflammation. Overall, these data support the hypothesis that blocking mTORC1 signaling and/or tissue inflammation can effectively inhibit prostate cancer progression in a relevant mouse model of human prostate cancer. Furthermore, combinatorial approaches that target both pathways may be highly effective for prevention of prostate cancer progression in men.

Citing Articles

Differential Effect of Non-Steroidal Anti-Inflammatory Drugs Aspirin and Naproxen against (Fusion)-Driven and Non-Fusion-Driven Prostate Cancer.

Raina K, Kandhari K, Kant R, Prasad R, Mishra N, Maurya A Cancers (Basel). 2023; 15(20).

PMID: 37894421 PMC: 10605633. DOI: 10.3390/cancers15205054.

Evaluation of the Combination of Metformin and Rapamycin in an MPP-Treated SH-SY5Y Model of Parkinson's Disease.

Norradee C, Khwanraj K, Balit T, Dharmasaroja P Adv Pharmacol Pharm Sci. 2023; 2023:3830861.

PMID: 36698448 PMC: 9870674. DOI: 10.1155/2023/3830861.

White adipose tissue-derived factors and prostate cancer progression: mechanisms and targets for interventions.

Saha A, Hamilton-Reeves J, DiGiovanni J Cancer Metastasis Rev. 2022; 41(3):649-671.

PMID: 35927363 PMC: 9474694. DOI: 10.1007/s10555-022-10056-0.

Autophagy: a multifaceted player in the fate of sperm.

Wang M, Zeng L, Su P, Ma L, Zhang M, Zhang Y Hum Reprod Update. 2021; 28(2):200-231.

PMID: 34967891 PMC: 8889000. DOI: 10.1093/humupd/dmab043.

Autophagy-targeted therapy to modulate age-related diseases: Success, pitfalls, and new directions.

Martins W, Silva M, Pandey K, Maejima I, Ramalho E, Olivon V Curr Res Pharmacol Drug Discov. 2021; 2:100033.

PMID: 34909664 PMC: 8663935. DOI: 10.1016/j.crphar.2021.100033.

References

Zakikhani M, Dowling R, Fantus I, Sonenberg N, Pollak M . Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 2006; 66(21):10269-73. DOI: 10.1158/0008-5472.CAN-06-1500. View

Tomimoto A, Endo H, Sugiyama M, Fujisawa T, Hosono K, Takahashi H . Metformin suppresses intestinal polyp growth in ApcMin/+ mice. Cancer Sci. 2008; 99(11):2136-41. PMC: 11159964. DOI: 10.1111/j.1349-7006.2008.00933.x. View

Klein E . Chemoprevention of prostate cancer. Annu Rev Med. 2006; 57:49-63. DOI: 10.1146/annurev.med.57.121304.131435. View

Singh S, Warin R, Xiao D, Powolny A, Stan S, Arlotti J . Sulforaphane inhibits prostate carcinogenesis and pulmonary metastasis in TRAMP mice in association with increased cytotoxicity of natural killer cells. Cancer Res. 2009; 69(5):2117-25. PMC: 2683380. DOI: 10.1158/0008-5472.CAN-08-3502. View

Mura M, Swain R, Zhuang X, Vorschmitt H, Reynolds G, Durant S . Identification and angiogenic role of the novel tumor endothelial marker CLEC14A. Oncogene. 2011; 31(3):293-305. DOI: 10.1038/onc.2011.233. View

Ben Sahra I, Regazzetti C, Robert G, Laurent K, Le Marchand-Brustel Y, Auberger P . Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res. 2011; 71(13):4366-72. DOI: 10.1158/0008-5472.CAN-10-1769. View

Akinyeke T, Matsumura S, Wang X, Wu Y, Schalfer E, Saxena A . Metformin targets c-MYC oncogene to prevent prostate cancer. Carcinogenesis. 2013; 34(12):2823-32. PMC: 3845895. DOI: 10.1093/carcin/bgt307. View

Dallaglio K, Bruno A, Cantelmo A, Esposito A, Ruggiero L, Orecchioni S . Paradoxic effects of metformin on endothelial cells and angiogenesis. Carcinogenesis. 2014; 35(5):1055-66. PMC: 4004203. DOI: 10.1093/carcin/bgu001. View

Raina K, Rajamanickam S, Deep G, Singh M, Agarwal R, Agarwal C . Chemopreventive effects of oral gallic acid feeding on tumor growth and progression in TRAMP mice. Mol Cancer Ther. 2008; 7(5):1258-67. DOI: 10.1158/1535-7163.MCT-07-2220. View

10.

Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P . The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene. 2008; 27(25):3576-86. DOI: 10.1038/sj.onc.1211024. View

11.

van Poppel H, Tombal B . Chemoprevention of prostate cancer with nutrients and supplements. Cancer Manag Res. 2011; 3:91-100. PMC: 3097798. DOI: 10.2147/CMR.S18503. View

12.

Gibbons J, Abraham R, Yu K . Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth. Semin Oncol. 2009; 36 Suppl 3:S3-S17. DOI: 10.1053/j.seminoncol.2009.10.011. View

13.

Blando J, Portis M, Benavides F, Alexander A, Mills G, Dave B . PTEN deficiency is fully penetrant for prostate adenocarcinoma in C57BL/6 mice via mTOR-dependent growth. Am J Pathol. 2009; 174(5):1869-79. PMC: 2671275. DOI: 10.2353/ajpath.2009.080055. View

14.

Hirsch H, Iliopoulos D, Struhl K . Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth. Proc Natl Acad Sci U S A. 2013; 110(3):972-7. PMC: 3549132. DOI: 10.1073/pnas.1221055110. View

15.

Kremer C, Klein R, Mendelson J, Browne W, Samadzedeh L, Vanpatten K . Expression of mTOR signaling pathway markers in prostate cancer progression. Prostate. 2006; 66(11):1203-12. DOI: 10.1002/pros.20410. View

16.

Kim S, Choi H . Metformin inhibits inflammatory response via AMPK-PTEN pathway in vascular smooth muscle cells. Biochem Biophys Res Commun. 2012; 425(4):866-72. DOI: 10.1016/j.bbrc.2012.07.165. View

17.

Clegg N, Couto S, Wongvipat J, Hieronymus H, Carver B, Taylor B . MYC cooperates with AKT in prostate tumorigenesis and alters sensitivity to mTOR inhibitors. PLoS One. 2011; 6(3):e17449. PMC: 3048873. DOI: 10.1371/journal.pone.0017449. View

18.

Sabatini D, Barrow R, Blackshaw S, Burnett P, Lai M, Field M . Interaction of RAFT1 with gephyrin required for rapamycin-sensitive signaling. Science. 1999; 284(5417):1161-4. DOI: 10.1126/science.284.5417.1161. View

19.

DeCensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B . Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila). 2010; 3(11):1451-61. DOI: 10.1158/1940-6207.CAPR-10-0157. View

20.

Center M, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O . International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012; 61(6):1079-92. DOI: 10.1016/j.eururo.2012.02.054. View